# US 5,703,108 A · Bone deposition by certain prostaglandin agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,703,108 A
- Document ID: US5703108A
- Status: Granted
- Kind: A
- Application number: 08/803,307
- Filed: 1997-02-20
- Granted: 1997-12-30
- Earliest claimed: 1997-02-20
- Assignees: Pfizer Inc.
- Inventors: Kimberly O. Cameron; Paul A. Dasilva-Jardine; Robert L. Rosati
- Web page: https://patentgrep.com/patent/US5703108A

## CPC

- A61K 31/559: having heterocyclic rings containing hetero atoms other than oxygen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for the treatment of bone disorders utilizing certain prostaglandin agonists/antagonists.

## Claims

### Claim 1

A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass a therapeutically effective amount of a compound of Formula I ##STR29## or a pharmaceutically-acceptable cationic salt thereof wherein Ar is 3-thienyl, 5(C.sub.1 -C.sub.4 alkyl)-2-thienyl, 5(C.sub.1 -C.sub.4 alkyl)-3-thienyl, .alpha.-napthyl, .beta.-napthyl, tropyl, 3,4-methylenedioxyphenyl;
R is H or methyl;
W is a single bond or a cis double bond;
Z is a single bond or a trans double bond; and
M and Q are each independently carbonyl, ##STR30##

### Claim 2 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is a single bond;
Z is a single bond;
Q is ##STR31## and Ar is 3,4-methylenedioxyphenyl.

### Claim 3 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is a single bond;
Z is s trans double bond;
Q is ##STR32## and Ar is 3,4-methylenedioxyphenyl.

### Claim 4 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is s cis double bond;
Z is a single bond;
Q is ##STR33## and Ar is 3,4-methylenedioxyphenyl.

### Claim 5 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is a cis double bond;
Z is a trans double bond;
Q is ##STR34## and Ar is 3,4-methylenedioxyphenyl.

### Claim 6 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is a single bond;
Z is a single bond;
Q is ##STR35## and Ar is 3,4-methylenedioxyphenyl.

### Claim 7 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is a single bond;
Z is a trans double bond;
Q is ##STR36## and Ar is 3,-methylenedioxyphenyl.

### Claim 8 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is a cis double bond;
Z is a single bond;
Q is ##STR37## and Ar is 3,4-methylenedioxyphenyl.

### Claim 9 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
W is a cis double bond;
Z is a trans double bond;
Q is ##STR38## and Ar is 3,4-methylenedioxyphenyl.

### Claim 10 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
Q is ##STR39## and Ar is 3-thienyl.

### Claim 11 (depends on 1)

A method as recited in claim 1 wherein
R is H;
W is a cis double bond;
Z is a trans double bond;
M is carbonyl;
Q is ##STR40## and Ar is 3-thienyl.

### Claim 12 (depends on 1)

A method as recited in claim 1 wherein
R is H;
M is carbonyl;
Q is ##STR41## and Ar is 3-thienyl.

### Claim 13 (depends on 1)

A method as recited in claim 1 wherein
R is H;
W is a cis double bond;
Z is a trans double bond;
M is carbonyl;
Q is ##STR42## and Ar is 3-thienyl.

### Claim 14 (depends on 1)

A method as recited in claim 1 wherein the condition is osteoporosis.

### Claim 15 (depends on 1)

A method as recited in claim 1 wherein about 0.001 to 100 mg/kg/day of the Formula I compound is administered.

### Claim 16 (depends on 15)

A method as recited in claim 15 wherein about 0.01 to 10 mg/kg/day of the Formula I compound is administered.